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Abstract 32 
The use of tramadol is a controversial topic in cycling. In order to provide novel evidence on 33 
this issue, we tested 29 participants in a pre-loaded cycling time trial (TT; a 20-min TT 34 
preceded by 40-min of constant work-rate at 60% of the VO2max) after ingesting 100 mg of 35 
tramadol (vs placebo and paracetamol (1.5 g)). Participants performed the Psychomotor 36 
Vigilance Task (PVT) at rest and a Sustained Attention to Response Task (SART) during the 37 
60 min of exercise. Oscillatory electroencephalography (EEG) activity was measured 38 
throughout the exercise. The results showed higher mean power output during the 20-min TT 39 
in the tramadol vs. paracetamol condition, but no reliable difference was reported between 40 
tramadol and placebo (nor paracetamol vs. placebo). Tramadol resulted in faster responses 41 
in the PVT and higher heart rate during exercise. The main effect of substance was reliable in 42 
the SART during the 40-min constant workload (no during the 20-min TT), with slower reaction 43 
time, but better accuracy for tramadol and paracetamol than for placebo. This study supports 44 
the increased behavioural and neural efficiency at rest for tramadol but not the proposed 45 
ergogenic or cognitive (harmful) effect of tramadol (vs. placebo) during self-paced high 46 
intensity cycling. 47 
 48 
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Introduction 54 
 55 
The debate about the use of tramadol in cycling has pervaded the sport’s environment1. 56 
Athletes have been shown to take tramadol and other analgesics in an attempt to have relief 57 
from the pain and fatigue that are typical components of an endurance sport like cycling2. 58 
Indeed, there is a wealth of literature on the effectiveness of tramadol in therapy for 59 
musculoskeletal pain, its efficacy, safety, and tolerability3–5. The mechanism of action of 60 
tramadol is two-fold, as a m-opioid receptor agonist, and as a serotonin and norepinephrine 61 
reuptake inhibitor, enhancing inhibitory effects on pain transmission in the spinal cord3,5. In 62 
addition to the potential ergogenic effect due to its analgesic and stimulant properties, 63 
concerns have been raised in regard to side-effects like dizziness and somnolence6 that could 64 
increase the likelihood of attentional lapses (impaired sustained attention) compromising the 65 
safety of the cycling peloton7.  These issues led the WADA to include tramadol in its monitoring 66 
program of doping substances since 20128. The Union Cycliste Internationale (UCI) has taken 67 
an even more extreme position, banning tramadol in competition from the 1st of March 20197. 68 
However, these concerns are not supported by solid empirical evidence about the ergogenic, 69 
or potentially harmful (cognitive), effects of this substance.  70 
To the best of our knowledge, only three randomized controlled trials (RCT) have 71 
investigated the potential ergogenic effect of tramadol on cycling performance9,10. The first 72 
RCT conducted on this matter9 showed a ~5% performance (power output) improvement in a 73 
20-min indoor cycling time trial (TT), a result that was not replicated in a further experiment 74 
reported in the same manuscript, nor in a more recent study by Bejder et al.10 (who tested 75 
participants in a 15km TT preceded by 1h constant work-rate at 60% of peak power). Crucially, 76 
neither Holgado et al.9 (Experiment 2) nor Bejder et al.10 found any effect of tramadol at the 77 
cognitive (attention) level. However, Holgado et al.9 (Experiment 2) did show reliable 78 
differences between tramadol and placebo conditions in event-related 79 
electroencephalographic (EEG) oscillatory activity (from the attentional task performed during 80 
the cycling TT) that hinted at a possible attentional effect of tramadol.  81 
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The scarce and mixed evidence described above motivated the present research, which 82 
aims to test the hypothesis that tramadol improves cycling (physical) performance at the 83 
expense of the ability to stay focused (indexed by both behavioural and EEG measures). 84 
Together with placebo, we included paracetamol as a further control condition. Paracetamol 85 
is another legal mild analgesic, popular among athletes11, and previously shown to elicit 86 
ergogenic effects in cycling11,12 (although as with tramadol, the evidence is still weak). The 87 
exact mechanism by which paracetamol achieves its pain-relieving effect is unclear, although 88 
research has suggested it may be due to the inhibition of the cyclooxygenase enzymes, 89 
potentiation of descending serotoninergic pathways, and modulation of opioid and 90 
cannabinoid CB1 receptors13. The dose of tramadol, paracetamol and a placebo were 91 
ingested prior to a pre-loaded TT, i.e., 40-min constant work-rate at 60% of peak power output 92 
followed by 20-min indoor TT. The purpose of the 40-min constant work-rate was to induce 93 
fatigue, maximizing the effect of the analgesics during the 20-min TT (see Bejder et al.,10 for 94 
a similar procedure), an useful test for assessing performance in trained cyclists14. 95 
 96 
Materials and Methods  97 
Study Design 98 
The study was a randomized, double blind and placebo-controlled trial. All experimental 99 
procedures were designed to comply with the Declaration of Helsinki and Good Clinical 100 
Practice (GCP). The Spanish Agency of Medicines and Medical Devices (AEMPS) -EudraCT 101 
number 2018-000388-10-, and the Ethical Committee of Clinical Research of University of 102 
Granada approved the trial. The randomization process, the audit and verification of 103 
compliance of GCP rules was performed by Foundation for the Biosanitary Research of 104 
Eastern Andalusia (FIBAO) in collaboration with Adknoma Health Research S.L. company. 105 
The method and planned analyses of this study were pre-registered on the Open Science 106 
Framework (April 25, 2018 update January 01, 2020: https://osf.io/2f4vq/). All data were 107 
entered in a case report form and subsequently in a computerized and scripted database, 108 
stored at the Mind, Brain and Behaviour Research Center (CIMCYC, University of Granada). 109 
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 110 
Participants 111 
The calculation of the sample size was based on an expected medium effect size (ηp2 = 112 
0.16). An a priori power analysis (using G* Power Version 3.1)15 recommended testing 28 113 
participants to detect that effect with a statistical power of 0.8. We decided to test 30 114 
participants to increase the statistical power and to account for possible drop out. Therefore, 115 
we recruited 30 moderately trained male participants who were enrolled by local 116 
advertisements. They were cyclists and triathletes with an age ranging from 18 to 40 years. 117 
Exclusion criteria were the presence of symptomatic cardiopathy, metabolic disorders such as 118 
obesity (BMI >30) or diabetes, chronic obstructive pulmonary disease, epilepsy, therapy with 119 
ß-blockers and medications that would alter cardiovascular function, hormonal therapy and 120 
smoking16. Moreover, the existence of allergy to tramadol and paracetamol or any excipients 121 
was considered. Participants were excluded from recruitment if they reported high levels of 122 
regular alcohol consumption, or use of recreational drugs (e.g., heroin, cocaine, etc.) for at 123 
least one year.   124 
One participant could not complete the study due to nausea, vomiting and dizziness after 125 
tramadol ingestion (approximately 130 min after Time 0). The final sample included 29 126 
participants. The participants’ characteristics are displayed in Table 1. 127 
 128 
Procedures 129 
Each participant visited the CIMCYC in four separate occasions. The first visit was 130 
dedicated to a maximal incremental test and familiarization with cognitive task and the 20-min 131 
TT. During the second, third, and fourth visits, a dose of tramadol and placebo, paracetamol 132 
and placebo, or two doses of placebo were administered to participants before starting the 133 
cycling exercise according to the randomization. No less than three days were allowed 134 
between experimental sessions to allow time for washout17 and all sessions were carried out 135 
within two weeks.  136 
During the first visit, all participants read and signed an informed consent form. Then, 137 
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descriptive anthropometric parameters of weight, height and body mass index, as well as 138 
information about cycling experience (i.e., years of practice, competition, etc.) were obtained 139 
from each participant. Participants then undertook a maximal incremental exercise test to 140 
exhaustion. 141 
The participants completed a 5 min warm-up at 90 Watts (W) on a cycle ergometer using 142 
their preferred cadence (within the range of 60 – 90 pedal revolutions per minute). They were 143 
asked to maintain this cadence throughout the rest of the protocol. The incremental exercise 144 
test started at 100 W and then increased at a rate of 30 W min-1 until volitional exhaustion (or 145 
when cadence fell > 10 rpm below the self-selected rate). Heart Rate (HR) and cycling 146 
resistance (W) were continuously monitored, and expiratory ventilation (VE), oxygen (O2) 147 
consumption rate (VO2), rate of CO2 production (VCO2), and respiratory exchange ratio (RER) 148 
we recorded on a breath-by-breath basis. Participants were verbally encouraged throughout 149 
to achieve their maximal performance. The test was considered maximal if one of the following 150 
criteria was met: 1) final HR within 10% of predicted maximum (220-age); 2) a clear plateau 151 
in oxygen uptake noticed; or 3) respiratory exchange ratio equal to, or above, 1.116.  152 
Before leaving the laboratory, participants read a page with standardized written 153 
instructions in order to familiarize with the 6-20 Borg scale18.  154 
At least 48h after the maximal incremental test, participants visited the laboratory for the 155 
second session. Participants abstained from physical activity, alcohol and caffeine 24h before 156 
the test. The same pre-exercise meal was kept before starting the experimental sessions. 157 
Upon arrival, they completed a 5 min version of the Psychomotor Vigilance Task (PVT; see 158 
details below). Immediately after, a single dose of oral tramadol or placebo (depending on the 159 
randomization) was administered to participants (Time 0). Then, they rested in the laboratory. 160 
After 90 min from Time 0, the participants ingested a single dose of paracetamol or placebo 161 
(see Fig. 1, black columns; Time 90). The administration time was based on previous empirical 162 
evidence19–21 documenting the time-course plasma paracetamol concentration in order to 163 
maximize its effect. As noted above, including a placebo dose at Time 90 in the tramadol and 164 
placebo experimental sessions ensured that we controlled for the number of capsules 165 
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ingested by the participants, crucial to maintain the double-blind procedure. Once participants 166 
ingested the substances, they were prepared for EEG measurement in a dimly-illuminated, 167 
sound-attenuated Faraday cage. After 105 min from Time 0 participants performed a second 168 
5 min PVT task. In order to record the resting EEG activity, participants were then encouraged 169 
to stay as relaxed as possible during 5 min with their eyes open. Next, participants warmed-170 
up for 5 minutes on the cycle ergometer prior to performing a 40-min constant work-rate at 171 
60% of their VO2max (commenced 120 minutes after Time 0). During the constant work-rate 172 
bout, participants were required to simultaneously perform a cognitive task (SART, see details 173 
below). At the end of the 40 min exercise, participants were asked to provide a rating of their 174 
perceived exertion (RPE) using the 6-20 Borg scale18.  175 
Immediately after the submaximal cycling trial, participants performed a 20-min cycling TT 176 
in which they were asked to achieve the highest average power output possible. Participants 177 
continued responding to the SART task during the 20-min TT. Immediately following the 20-178 
min TT participants were again asked to provide a rating of their perceived exertion using the 179 
Borg RPE scale18. At the end of the experimental visit, and after 24h, participants were 180 
contacted to ask about any adverse events (if yes: mild / moderate / serious). 181 
The procedures for visits 3 and 4 were similar to that in visit 2 (each athlete began the test 182 
at visits 3 and 4 as the same time as in visit 2), except that participants ingested the other 183 
substances or a placebo, depending on the randomization. 184 
 185 
Materials 186 
An SRM indoor cycle ergometer (Jülich, Germany) was used for all cycling trials. A 187 
RS800CX Polar monitor (Polar Electro, Finland) was used to monitor and record (via a sensor 188 
band attached to the participants’ chest) Heart Rate (HR) of the participants during the 189 
experiments. A Jaeger Master Screen gas analyzer (CareFusion GmbH, Germany) was used 190 
to collect gaseous exchange data during the maximal incremental test. A computer and the 191 
Psychtoolbox were used to control stimulus presentation, response collection, and to generate 192 
and send triggers indicating the onset of each period. Behavioural and EEG data pre-193 
8 
 
processing, and analysis were conducted using a combination of custom Matlab scripts 194 
(Matlab 2014a, Mathworks Inc.), and the EEGLAB23 and Fieldtrip24 Matlab’s toolboxes. 195 
 196 
Tramadol and paracetamol doses 197 
In this clinical trial, we administered a 100 mg oral dose of tramadol. According to an 198 
exhaustive review by Grond and Sablotzki3 tramadol is rapidly absorbed with a bioavailability 199 
of about 70% after single doses and it is eliminated with a half-life of about 5.6 h3,25. 200 
Importantly, Bastami et al.26 identified good tolerability to doses of 100 mg of tramadol, 201 
showing a mean time to maximum plasma concentration of 156 min (range: 87–208 min). In 202 
our previous study9, we confirmed the same tolerability to adverse events.  203 
Paracetamol is metabolized mainly in the liver via glucuronidation (50-60%), sulfation (25-204 
30%) and oxidation (< 10%)13. This non-opioid analgesic has an excellent tolerance, for 205 
therapeutic doses and is a major reason for its recommendation and widespread approbation 206 
as an analgesic27. In this study participants took a capsule containing 1.5 g of paracetamol. 207 
This dose was based on previous empirical evidence on plasma paracetamol concentration 208 
to maximize the effect27–29. 209 
All oral doses were prepared at the Hospital “Virgen de las Nieves” pharmacology 210 
department (Granada, Spain). The doses were made following the good manufacturing 211 
practice (GMP) audit and approved by Spanish authorities (i.e., AEMPS). Only the pharmacist 212 
knew the content of the randomization list. Each capsule was packed in a monodose blister 213 
with the patient code and visit number on the information label. The placebo dose was 214 
composed of microcrystalline cellulose.  215 
 216 
Cognitive tasks 217 
Psychomotor Vigilance Task (PVT) 218 
We used a modified version of the PVT proposed by Wilkinson and Houghton30. This task 219 
was developed to measure sustained attention by recording participants’ reaction time (RT) 220 
to visual stimuli that occur at random inter-stimulus intervals. Each trial began with the 221 
9 
 
presentation of a blank screen in a black background for 2000 ms and subsequently, an empty 222 
red circle (i.e., cue stimulus, 6.68° Å~ 7.82° of visual angle at a viewing distance of 60 cm) 223 
appeared in a black background. Following a random time interval (between 2000 and 10000 224 
ms), the circle was also filled with a red colour (i.e., target stimulus). The instruction given to 225 
participants was to respond as fast as they could, once they had detected the presentation of 226 
filled red circle, which was presented for 500 ms with a maximum time to respond of 1500 ms. 227 
RTs <100 ms were considered anticipations and we discarded from the analysis. Participants 228 
had to press the space bar on the keyboard with their dominant hand. The task involved a 229 
single block of 5 minutes. 230 
 231 
Sustained Attention to Response Task (SART) 232 
We used a modified version of the SART as documented by Robertson et al31. The task 233 
consisted of a sequential presentation of numbers ranging between 1 and 9. Participants were 234 
instructed to respond by pressing a button connected to the cycle-ergometer handlebar with 235 
the thumb of their dominant hand as quickly as possible upon the presentation of each number 236 
(Go trials), except for the number “3”, which they had to ignore (NoGo trials). Stimuli appeared 237 
in white colour over a black background at the centre of the computer screen in one of five 238 
possible font sizes (48, 72, 94, 100 and 120 points, Times New Roman). Each trial started 239 
with the presentation of a white cross on a black background for 800 ms. Stimuli were 240 
presented at a random time interval (between 0 and 100 ms) for 150 ms. Participants had a 241 
1100 ms time-window to respond to the stimuli. Stimuli were distributed in a quasi-random 242 
fashion to avoid the presentation of two consecutive NoGo trials. Participants completed the 243 
task during both the 40-min constant work-rate test and the 20-min TT. The data set was then 244 
divided in blocks of 10 min for analytical purposes to study the potential effect of time-on-task 245 
(induced fatigue), and the interaction with the substances. Participants were familiarized with 246 
the task during the first laboratory visit. 247 
 248 
EEG recording analysis  249 
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Continuous EEG data were recorded at 1000 Hz using a 30-channel actiCHamp System 250 
(Brain Products GmbH, Munich, Germany) with active electrodes positioned according to the 251 
10–20 EEG International System and referenced to the Cz electrode. The cap was adapted 252 
to the participant’s head size, and each electrode was filled with Signa Electro-Gel (Parker 253 
Laboratories, Fairfield, NJ) to optimize signal transduction. Participants were instructed to 254 
avoid body movements as much as possible, and to keep their gaze on the centre of the 255 
screen during the exercise. Electrode impedances were kept below 10 kΩ throughout the 256 
recording. To ensure an acceptable signal-to-noise ratio and to reduce the type I error rate 257 
possibility by post hoc exclusion of participants, we set an a priori criteria of 75% of artefact-258 
free trials per subject and substance32,33. EEG data were resampled at 500 Hz, bandpass 259 
filtered offline from 1 and 40 Hz to remove signal drifts and line noise and to a common 260 
average reference. Horizontal electrooculograms were recorded by bipolar external 261 
electrodes for the offline detection of ocular artefacts. Independent component analysis was 262 
used to confirm and remove EEG components reflecting blinks and other eye movements34. 263 
Electrodes presenting abnormal power spectrum were identified via visual inspection and 264 
replaced by spherical interpolation.  265 
 266 
Spectral power analysis 267 
Pre-processed EEG data from each experimental period (baseline, warm-up, 40-min 268 
constant work-rate test, 20-min TT) were segmented into 1-s epochs. The spectral 269 
decomposition of each epoch was computed using Fast Fourier Transformation (FFT) 270 
applying a symmetric Hamming window (0.5 s). The obtained power values were averaged 271 
across experimental periods. 272 
 273 
Time-frequency analysis 274 
Task-evoked spectral EEG activity was assessed by computing event-related spectral 275 
perturbations in epochs extending from −100 ms to 300 ms time-locked to stimulus onset for 276 
frequencies between 4 Hz and 40 Hz. Spectral decomposition was performed using sinusoidal 277 
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wavelets with three cycles at the lowest frequency and increasing by a factor of 0.8 with 278 
increasing frequency. Power values were normalized with respect to a −300 ms to 0 ms pre-279 
stimulus baseline and transformed into the decibel scale (10*log10 of the signal). 280 
 281 
Statistical analysis  282 
Baseline-corrected (Post–Pre/Post+Pre) RT data from the PVT were analyzed using a 283 
within-participants’ ANOVA with the factor of substance (tramadol, paracetamol, placebo). The 284 
RT for Go trials on the SART, and false alarms (errors) for the NoGo trials were analyzed by 285 
a within-subjects ANOVA with the factors of substance (tramadol, paracetamol, placebo) and 286 
block (x 4 for the 40 min constant intensity exercise period and x 2 for the 20 min TT period).  287 
Exercise performance data (power output and HR) were analyzed using a within-288 
participants’ ANOVA with the factors of substance (tramadol, paracetamol, placebo) and time-289 
on-task (x 4 blocks of 10 min in the case of the 40 min constant intensity exercise period and 290 
x 2 blocks of 10 min for the 20 min TT period). A one-way within-subjects ANOVA was used 291 
to analyze the RPE data. ANOVAs were followed up by post hoc pairwise comparisons with 292 
Holm-Bonferroni.  293 
A stepwise, cluster-based, non-parametric permutation test approach35 without prior 294 
assumptions on any frequency range or brain area of interest, was used to examine the 295 
spectral power differences between substances (tramadol, paracetamol, placebo), separately 296 
at each period (baseline, warm-up, 40-min constant work-rate test and 20-min TT). We 297 
performed a t-test for dependent samples on all individual electrodes and frequency pairs (30 298 
channels, 40 frequencies), clustering samples with t-values that exceeded a threshold (p < 299 
0.025) based on spatial and spectral adjacency. This procedure was repeated 5,000 times to 300 
estimate the distribution of maximal cluster‐level statistics obtained by chance. The proportion 301 
of random partitions that resulted in a larger test statistic than the original determined the two‐302 
tailed Monte Carlo p value (see Holgado et al.,36 for a similar approach). 303 
Event-related spectral perturbation main differences of substance (tramadol, paracetamol, 304 
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placebo) for each stimulus of the SART (Go, NoGo) were also analyzed by applying the 305 
cluster-based permutation test. In order to reduce the possibility that the type II error rate was 306 
inflated by multiple comparisons correction, we set an a priori criteria of collapsing data into 307 
four frequency bands: Theta (4–8 Hz), Alpha (8–14 Hz), lower Beta (14–20 Hz) and upper 308 
Beta 1 (20–40 Hz). To avoid an overlap with behavioural responses, we limited the time 309 
windows of interest to the first 300 ms after the stimuli onset (based on average behavioral 310 
response times) for Go trials. 311 
The raw physical performance, EEG and behavioural data, as well as Matlab custom 312 
scripts are available at the OSF repository: https://osf.io/2f4vq/ 313 
 314 
Results 315 
 316 
Modified PVT task 317 
The analysis of the baseline-corrected RT data for the modified PVT revealed a main 318 
effect of substance, F (2,56) = 5.76, p = 0.005, ηp2 = 0.17 [0.03 - 0.29]. Post-hoc comparisons 319 
showed that participants were faster in the tramadol condition: -0.003 95% CI [-0.0154 – 320 
0.0097] in comparison to paracetamol: 0.013 95% CI [0.0051 – 0.0219], t(2) = 2.78,  p = 0.026, 321 
Cohen’s d = 0.51 [0.19 – 1.25]; and placebo: 0.017 95% CI [0.0100 – 0.0255] ms);  t(2) = 2.82,  322 
p = 0.026, Cohen’s d = 0.52 [0.20 – 1.27] (see Table 2).  323 
 324 
Physical performance 325 
The analysis of the average power output during the 20-min TT revealed a main effect of 326 
substance, F (2, 56) = 4.408, p = 0.017, ηp2 = 0.13 [0.01 - 0.25] (see Fig. 2A). Post-hoc 327 
comparisons only revealed a reliable difference between tramadol (227 W, 95% CI [215.6 – 328 
238.1]) and paracetamol (213 W 95% CI [99.4 – 227.3]), t (2) = 3.753, p =.002, Cohen’s d = 329 
0.69 [0.43 – 1.52]). Crucially, neither the difference between tramadol and placebo (221 W 330 
95% CI [207.6 – 233.7]), t(2) = 1.242, p =0.3, Cohen’s d = 0.23 [-0.19 – 0.84] nor that between 331 
placebo and paracetamol were reliable  (t(2) = 1.48, p = 0.3, Cohen’s d = 0.27 [-0.13 – 0.9). 332 
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Neither the main effect of block: F (1, 28) = 2.02, p = 0.16, ηp2 = 0.06 [0 – 0.23] nor the 333 
interaction between substance and block F (2, 56) = 2.71, p = 0.07, ηp2 = 0.08 [0 – 0.19] 334 
reached statistical significance (see Fig. 2B).  335 
 336 
Heart rate 337 
The HR values collected during the 40-min constant work-rate test period evidence of a 338 
main effect of substance F (2,56) = 7.636), p = 0.001, ηp2 = 0.21 [0.06 – 0.34]. Post-hoc 339 
comparisons revealed higher HR for tramadol (144 bpm, 95% CI [140 – 149]) than for 340 
paracetamol (139 bpm, 95% CI [135 – 135], t(2)= 3.65, p = 0.003, Cohen’s d = 0.67 [0.41 – 341 
1.49]) and placebo (139 bpm, 95% CI [134 – 144], t(2) = 3.06, p = 0.01, Cohen’s d = 0.56 [0.26 342 
– 1.35). A main effect of Block, F (3,84) = 38.139), p < 0.001, ηp2 = 0.57 [0.44 – 0.64] was also 343 
found. HR was higher in blocks 2 t(3)= 8.68, p < 0.001, Cohen’s d = 1.61 [1.60 – 2.29], 3 t(3) 344 
= 7.26, p < 0.001, Cohen’s d = 1.35 [1.27 –  2.52] and 4 t(3)= 7.41, p < 0.001, Cohen’s d = 345 
1.37 [1.31 – 2.56] compared with block 1, and in block 4 compared with block 2; t(1)= 3.61, p 346 
= 0.007, Cohen’s d = 0.62 [0.40 – 1.48]. Nonetheless, the interaction between substance and 347 
block was again not reliable F (6,168) = 1.47), p = 0.19, ηp2 = 0.05 [ 0 - 0.07]. 348 
During the 20-min TT, HR values showed a main effect of substance, F (2,56) = 6.160, p 349 
= 0.004, ηp2 = 0.18 [0.03 – 0.3]. Post-hoc comparisons yielded significant differences between 350 
tramadol and placebo (t(2) = -2.681; p = 0.024, Cohen’s d = -0.49 [-1.23 - -0.16]) and between 351 
tramadol and paracetamol (t(2) = -3.809; p = 0.002, Cohen’s d = -0.70 [-1.54 - -0.44]). 352 
Participants had higher HR values in the tramadol condition [162 bpm 95% CI (156.8 – 167.2)] 353 
than in the paracetamol [153 bpm 95%CI (146.2 – 159.4)] and placebo conditions [154 bpm 354 
95% CI (146.4 – 161)]. There was also a main effect for block, F (1,28) = 25.817, p < 0.001, 355 
ηp2 = 0.48 [0.23 – 062], with HR being higher in the second block: 158 95% CI (153.35 – 164.24 356 
than in the first block: 153 95% CI (147.8 – 159.0) t(1) = -5.081; p = 0.001, Cohen’s d = -0.94 357 
[-1.91 - -0.75]). The interaction between substance and block was not reliable , F (2,56) = 358 
2.45, p = 0.09, ηp2 = 0.08 [0 – 0.18]. 359 
 360 
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Subjective scales 361 
The analysis of rating of perceived exertion showed reliable differences between the three 362 
substances after the 40-min constant work-rate, F (2, 56) = 6.96, p = 0.002, ηp2 = 0.19 [0.05 – 363 
0.32]. Post-hoc comparisons yielded reliable differences between tramadol and placebo t(2) 364 
= 3.35; p = 0.007, Cohen’s d = 0.62 [0.33 – 1.41]) and between tramadol and paracetamol 365 
(t(2) = 3.05; p = 0.01, Cohen’s d = 0.56 [0.26 – 1.33]). RPE values were lower in the tramadol 366 
condition [13, 95%CI (12.7 – 14.1)], than in the placebo condition [14, 95%CI (13.8 – 15.36)] 367 
and paracetamol condition [14, 95%CI (13.6 – 15.3)]. However, there were not any reliable 368 
differences in RPE between conditions for the 20-min TT, F (2, 56) = 0.85, p = 0.43, ηp2 = 0.03 369 
[0 – 0.1]. 370 
 371 
Sustained Attention to Response Task (SART) 372 
The analysis of the false alarms (NoGo trials) in the SART for the 40-min constant work-373 
rate test revealed a main effect of substance, F (2,50) = 4.25, p = 0.02, ηp2 = 0.14 [0.13 - 0.27]. 374 
There were more false alarms in the placebo condition (0.57 95% CI (0.41 - 0.62) than in 375 
paracetamol (0.43 95% CI (0.33 - 0.54) and tramadol (0.45 95% CI (.34 - 56), although post-376 
hoc comparisons did not yield reliable differences between substances t(2)= 2.42, p = 0.06, 377 
Cohen’s d = 0.47 [0.11 – 1.25] and t(2) < 0.77, p = 0.44, Cohen’s d = 0.15 [-0.53 – 0.57] 378 
respectively. Additionally, there was a main effect of block F (3,75) = 12.8, p < 0.001, ηp2 = 379 
0.33 [0.17 – 0.44]. Post-hoc comparisons showed that participants committed less false 380 
alarms in the first 10 minutes in comparison with 20 (t(3) = 3.39, p = 0.009, Cohen’s d = 0.66 381 
[0.36 – 1.54]), 30 (t(3) = 3.82, p = 0.004, Cohen’s d = 0.75 [0.48 – 1.67]) and 40 minutes (t(3) 382 
= 4.72, p < 0.001, Cohen’s d = 0.92 [0.71 – 1.94]). The interaction between substance and 383 
block was not reliable (F < 1). 384 
The analysis of the RT to Go trials for the 40-min constant work-rate test revealed a main 385 
effect of substance, F (2,50) = 4.67, p = 0.01, ηp2 = 0.15 [0.01 – 0.28]. Participants were faster 386 
in the placebo condition: 321 95% CI (296 - 347) ms; compared with the paracetamol: 354 387 
95% CI (314 - 395); and tramadol: 342 95% CI (302 - 381) ms, although post-hoc comparisons 388 
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did not yield reliable differences between substances. t(2) = 2.53, p = 0.054, Cohen’s d = 0.49 389 
[0.13 – 1.28] for placebo vs. paracetamol and t(2) = 1.89, p = 0.14, Cohen’s d = 0.37 [-0.03 – 390 
1.09] for placebo vs. tramadol. Additionally, there was a main effect of block F (3,75) = 4.01, 391 
p = 0.01, ηp2 = 0.13 [0.01 – 0.23]. Post-hoc comparisons showed faster RTs in the last 10 392 
minutes compared with the first 10 (t(3) = 4.45, p = 0.02, Cohen’s d = 0.6 [0.64 – 1.86]. The 393 
interaction between substance and block was not reliable F (6,1250) = 1.35, p = 0.23, ηp2 = 394 
0.05 [0.01 – 0.23].  395 
The analysis of the false alarms (NoGo) in the SART for the 20-min TT did not show a 396 
reliable main effect of substance or block (F < 1), or interaction between substance and block 397 
F (2,48) = 1.81 p = 0.17, ηp2 = 0.07 [0 – 0.18]. Similarly, there was no effect of substance F 398 
(2,48) = 1.89, p = 0.16, ηp2 = 0.07 [0 – 0.18] or block F (1,24) = 2.11, p = 0.15, ηp2 = 0.08 [0 – 399 
0.27] or interaction between substance and block F (2,48) =2.49, p = 0.09, ηp2 = 0.09 [0 – 0.21 400 
for the RT (to Go trials). 401 
 402 
EEG data 403 
Spectral power analysis 404 
The analysis of tonic spectral power revealed reliable differences between substances (p 405 
< 0.001, ηp2 = 0.81 [0.71 – 0.90) for the baseline period, in the frequency range of 21-40 Hz 406 
(23 electrodes), showing more power for tramadol than for placebo and paracetamol. The 407 
tonic spectral power analysis of the other periods (i.e., warm-up, 40-min constant work-rate 408 
test or the 20-min TT) yielded no reliable differences.  409 
 410 
Time-frequency analysis 411 
The time frequency analysis during the SART did not reveal any reliable differences 412 
between substances (tramadol, paracetamol, placebo) for any of the stimuli (Go, NoGo), either 413 
in the 40-min constant work-rate test or the 20-min TT (all clusters p ≥ 0.05; see Fig. 4). 414 
 415 
Adverse events 416 
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Three participants reported adverse symptoms (nausea, dizziness and vomiting) at the 417 
end of the tramadol experimental session. All manifested symptoms were moderate and 418 
disappeared within the next 24 hours. 419 
 420 
Discussion 421 
 422 
Tramadol has long been in the spotlight of the doping controversy in cycling. The current study 423 
aimed to test the potential ergogenic and cognitive (harmful) effects of this substance 424 
compared with placebo and paracetamol conditions. The main findings of the study suggests 425 
that 100 mg of tramadol did not induce changes in physical performance during a 20-min TT 426 
after 40 min of cycling exercise at 60% of VO2max. This result is consistent with that of Holgado 427 
et al.’s9  Experiment 2 and Bejder et al.10 but at odds with the findings of Holgado et al.’s9 428 
Experiment 1. These failed replications could be suggestive of a false positive from Holgado 429 
et al.’s9 Experiment 1, or be due to the inclusion of a cognitive task during the TT both in 430 
Holgado et al.’s9 Experiment 2, and in the present study that might have somehow reduced 431 
the effect of tramadol. Nevertheless, Bejder et al.10 did not include a cognitive task during their 432 
15 km TT and still failed to report an effect of tramadol on physical (and cognitive) 433 
performance. Apart from the presence or not of a cognitive task during the cycling effort, the 434 
other potentially relevant difference between studies was the inclusion of female participants 435 
in Holgado et al.’s9 Experiment 1 (other factors like the nutrition status, time of test day and 436 
exercise demands -time trial- were similar in the studies conducted in our laboratory; note that 437 
Bedjer et al.10 also used a TT as the exercise test). However, the data analyses of that 438 
experiment revealed that the effect of tramadol did not depend on participants’ gender (p = 439 
0.839), hence it would seem unlikely that this factor could explain the presence of the effect in 440 
Holgado et al.’s Experiment 1 in contrast to the other three studies. 441 
Tramadol did, however, exert an effect on physiological responses recorded during 442 
exercise. Similar to Bejder et al.’s study10 (4 bpm in the TT), tramadol induced higher HR than 443 
both placebo and paracetamol during the 40 min at 60% of VO2max and the 20-min TT. A 444 
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reliable difference between tramadol and placebo was also found in Holgado et al.'s9 445 
Experiment 1 (4 bpm). This outcome could be accounted for by tramadol’s action as both a 446 
serotonin and norepinephrine reuptake inhibitor, which can lead to cardiac effects37,38. 447 
However, the 8 bpm difference reported in the present study could be negligible in practical 448 
terms, as it was not followed by changes in performance. In addition, the lack of a reliable 449 
difference in Holgado et al.'s9 Experiment 2 hinders any explanation of the tramadol effect on 450 
HR.   451 
RPE was also higher in the tramadol condition, but only during the 40-min constant work-452 
rate task. Whatever the explanation for the HR and RPE results, they were not followed by a 453 
change in physical performance in the TT. Indeed, differences were reported only between 454 
tramadol and paracetamol conditions (227 vs 213  W, respectively; p =.002), with paracetamol 455 
showing even lower values than placebo, in contrast to previous studies 28,39,40, although that 456 
difference was not statistically reliable (213 vs 221 W, respectively; p = 0.3). 457 
At the cognitive level, our results suggest that tramadol did not impair the ability to stay 458 
focused during a high-intensity effort. Nevertheless, the accuracy and RT results yielded a 459 
statistically reliable effect of substance during the 40-min constant work-rate, although the lack 460 
of reliable pairwise comparisons between the three substances hinders any explanation. In 461 
any case, the reduced number of false alarms and larger RTs in the tramadol condition (vs. 462 
placebo) could be interpreted as a sign of enhanced cognitive control, i.e., better ability to 463 
inhibit undesired responses at the expense of being slower41. Moreover, tramadol induced the 464 
best PVT (baseline-corrected) performance at rest, and no substance effects were shown in 465 
the SART during the 20-min TT. These results, together with the overall increase of oscillatory 466 
brain activity after substance intake and prior to exercise, do not seem to support the notion 467 
that tramadol impairs the ability to stay focused. Instead, these effects at baseline could be 468 
due to the stimulant effect of the substance5.  469 
The absence of evidence is not evidence of the absence of an effect, and therefore our 470 
null findings could be accounted for by various factors (apart from the obvious lack of a true 471 
effect) including: i) 100 mg of tramadol might have not been enough to exert any effect in 472 
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performance (compared with placebo). Moreover, as with other previous research, the dose 473 
was not individualized (e.g., as a function of body weight), which might have included between-474 
participants variability because of a (potential) dose-response dependency of the tramadol 475 
effects on physical and cognitive performance; ii) all studies to date have only tested the 476 
effects of an acute dose of tramadol during exercise. However, the question remains as to 477 
whether a multi-day administration of tramadol (vs. placebo) might effectively induce 478 
ergogenic and (potential harmful) cognitive effects; iii) related to this, tramadol could provide 479 
a further benefit after days of prolonged and intense physical workloads as encountered during 480 
a multi-stage cycling tour; iv) tramadol induces a “true” but fairly small effect and so all studies 481 
on this matter to date could have been underpowered to detect it. 482 
The present results suggest that tramadol does not have any ergogenic effect or impair 483 
the ability to stay focused during a maximal cycling TT effort. Why do pro and amateur cyclists 484 
appear to be taking it to improve performance then? A true effect under any (or more than 485 
one) of the circumstances discussed in the paragraph above and/or a most than likely placebo 486 
effect (see Kayser, 2020, for discussion on this issue)42 could certainly explain the use (and 487 
potential abuse) of this substance. Given the relevance of this matter to sports in general, and 488 
cycling in particular, the typical final “further research is needed” clause in scientific papers 489 
seems more than appropriate here.  490 
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Table 1. Characteristics (mean ± SD) of the participants in the study.  607 
  
Age (years) 26 ± 7 
Weight (kg) 68.8 ± 7.5 
Height (cm) 175.3 ± 5.2 
Body mass index (kg/m2) 22.3 ± 2.2 
VO2max (ml/min/kg) 52.7 ± 6.3 
Maximal power output (W) 346 ± 29 
Power 60% of VO2max (W) 191 ± 16 
 608 
  609 
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Table 2. Mean ± Standard Deviation for the PVT data. 610 
Substance Pre Post Baseline-corrected 
TRA 278.2 ± 36.5 275.8 ± 28.3 -0.003 ± 0.033 
PAR 271.1 ± 27.0 278.3 ± 24.9 0.013 ± 0.021 
PLA 268.9 ± 26.4 278.6 ± 27.2 0.017 ± 0.020 
 611 
PAR, paracetamol; PLA, placebo; TRA, tramadol. Data are expressed in ms. 612 
 613 
  614 
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Figure legends  615 
 616 
Fig. 1. Experimental protocol in Day 2, 3 and 4. 617 
Note: Time (min): PVT: Psychomotor Vigilance Task (white columns). Black columns 618 
represent substances administration phase. Grey columns represent the EEG baselines, 619 
exercise and cognitive performance test (SART) and the RPE (6-20 Borg scale) 620 
measurement.  621 
 622 
Fig. 2. Power output in the 20-min TT as a function of substance (panel A), and as a function 623 
of substance and block (panel B (block 1, 0-10 min; block 2, 10-20 min).  624 
Panel A: TRA, tramadol; PAR, paracetamol; PLA, placebo. Panel B: Tramadol, red square; 625 
Paracetamol, black square; Placebo, blue square. Values are means and error bars indicate 626 
the standard deviation. 627 
 628 
Fig. 3. Average EEG power spectrum across all channels for paracetamol (black line), placebo 629 
(blue line) and tramadol (red line) substance at baseline, warm-up, 40-min constant work-rate 630 
test and 20-min TT period. Reliable differences between substances are marked by grey area, 631 
showing the higher spectral power for tramadol compared with placebo and paracetamol at 632 
baseline. 633 
 634 
Fig. 4. Event-related spectral perturbation during the SART. Event-locked spectral power 635 
averaged across all electrodes for each substance. Each panel illustrates time-frequency 636 
power across time (x-axes) and frequency (y-axes) for the Go and NoGo stimuli (blue: 637 
decreases; red: increases). Dashed vertical line represents stimulus onset. 638 
 639 
 640 
 641 
